Related Experiment Video
Updated: Mar 1, 2026
Author Spotlight: Enhancing Multicolor Fluorescence Localization in Lung Carcinoma Sample
Published on: November 21, 2023
Update on Immunohistochemical Analysis in Breast Lesions
Yan Peng, Yasmeen M Butt, Beiyun Chen
1From the Department of Pathology, University of Texas Southwestern Medical Center, Dallas (Drs Peng and Butt); the Department of Pathology, Mayo Clinic and Foundation, Rochester, Minnesota (Dr Chen); the Department of Pathology, Cooper Medical School of Rowan University, Camden, New Jersey (Dr Zhang); and the Department of Pathology and Laboratory Medicine, University of Rochester, Rochester, New York (Dr Tang).
Immunohistochemistry (IHC) aids in diagnosing breast lesions and distinguishing metastatic lung cancer from primary breast cancer. Novel IHC markers show promise for triple-negative breast carcinoma targeted therapies.
Area of Science:
- Oncology
- Pathology
- Molecular Diagnostics
Background:
- Immunohistochemistry (IHC) is crucial for diagnosing breast lesions, but its utility requires updates, especially for challenging cases.
- Distinguishing metastatic lung adenocarcinoma in the breast from primary breast carcinoma is vital due to differing prognoses and treatments.
- Triple-negative breast carcinoma (TNBC) is aggressive, necessitating research into targeted therapies via biomarker studies.
Observation:
- A literature review and author experience highlight the role of IHC in differential diagnoses of breast lesions.
- Recent findings on novel IHC markers for TNBC are presented.
- Real case examples illustrate IHC's importance in differentiating metastatic lung adenocarcinoma from primary breast carcinoma.
Findings:
- IHC is essential for diagnosing ambiguous breast lesions, with specific marker expressions aiding in challenging cases.
- Androgen receptor, p16, p53, GATA3, and PELP1 show potential diagnostic, prognostic, and predictive value in TNBC.
- A panel including napsin A, TTF-1, and GATA3 is effective for distinguishing metastatic lung adenocarcinoma from primary breast carcinoma.
Implications:
- Accurate IHC interpretation refines breast cancer diagnosis and classification.
- Understanding TNBC biology through novel markers may lead to new targeted therapies.
- Improved diagnostic accuracy for metastatic disease impacts patient management and treatment strategies.
